Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 7-17

  Brown, Thomas E ^a   Brams, Matthew ^b   Gao, Joseph ^c   Gasior, Maria ^c   Childress, Ann ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bayou City Research   (United States)

^c SHIRE   (United States)

^d Center for Psychiatry and Behavioral Medicine   (United States)

Author keywords

ADHD; Brown Attention Deficit Disorder Scale; Executive function; LDX; Lisdexamfetamine dimesylate; Vyvanse

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE;

ADHD RATING SCALE IV; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BRONCHITIS; BROWN ATTENTION DEFICIT DISORDER SCALE; CLUSTER ANALYSIS; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EXECUTIVE FUNCTION; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA; CLINICAL TRIAL; DOSE RESPONSE; MULTICENTER STUDY;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE;

EID: 78049518787     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2196     Document Type: Article

References (48)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
2. Brown TE. Executive functions and attention deficit hyperactivity disorder: Implications of two conflicting views. Int J Disability Develop Educ. 2006;53(1):35-46.
3. Castellanos FX, Sonuga-Barke EJ, Milham MP, Tannock R. Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci. 2006;10(3):117-123.
4. Barkley RA. Deficient emotional self-regulation is a core component of attention-deficit/hyperactivity disorder. In press. J ADHD Relate Disord.
5. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121(1):65-94.
6. Brown TE. DSM-IV: ADHD and executive function impairments. Adv Stud Med. 2002;2(25):910-914.
7. Brown TE. Brown Attention-Deficit Hyperactivity Disorder Scales for Adolescents and Adults. San Antonio, TX: The Psychological Corporation, Harcourt Assessment; 1996:1-102.
8. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: A meta-analytic review. Biol Psychiatry. 2005;57(11):1336-1346.
9. Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(10):1730-1738.
10. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004;18(3):485-503.
11. Doyle AE. Executive functions in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(suppl 8):21-26.
12. Nigg JT, Willcutt EG, Doyle AE, Sonuga-Barke EJ. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry. 2005;57(11):1224-1230.
13. Brown TE, Reichel PC, Quinlan DM. Executive function impairments in high IQ adults with ADHD. J Atten Disord. 2009;13(2):161-167.
14. Brown T. Attention Deficit Disorder: The Unfocused Mind in Children and Adults. New Haven, CT: Yale University Press; 2005.
15. Shallice T, Burgess PW. Deficits in strategy application following frontal lobe damage in man. Brain. 1991;114(pt 2):727-741.
16. Lawrence V, Houghton S, Tannock R, Douglas G, Durkin K, Whiting K. ADHD outside the laboratory: Boys' executive function performance on tasks in videogame play and on a visit to the zoo. J Abnorm Child Psychol. 2002;30(5):447-462.
17. Kooij JJS, Marije Boonstra A, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;11(4):445-458.
18. Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines. CADDRA 2008. http://www.caddra.ca/cms4/index.php?option=com_content&view=article&id=26&Itemid=353&lang=en. Accessed December 14, 2009.
19. Atkinson M, Hollis C. NICE guideline: attention deficit hyperactivity disorder. Arch Dis Child Educ Pract Ed. 2010;95(1):24-27.
20. Vyvanse [package insert]. Wayne, PA: Shire US Inc; 2010.
21. Adler LA, Goodman DW, Kollins SH, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373.
22. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct. 2010;6(1):34.
23. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450-463.
24. Wigal SB, Kollins SH, Childress AC, Squires L; 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.
25. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000:85-93.
26. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
27. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Attent Disord. 2001;5(2):107-115.
28. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892-1908.
29. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40(2):168-179.
30. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L; 304 Study Group. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2009;14(10):573-585.
31. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
32. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
33. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68(1):93-101.
34. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639.
35. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ; SLI381.304 Study Group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 suppl 20):16-25.
36. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L; Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380-1387.
37. Brown TE, Spencer TJ, Silverberg A, Youcha SH. Improved executive functions with triple-bead mixed amphetamine salts (spd465), a novel, enhanced extended-release amphetamine formulation, in adults with ADHD. Poster presented at: New Clinical Drug Evaluation Unit (NCDEU) 47th Annual Meeting; June 11-14, 2007; Boca Raton, FL.
38. Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006;22(12):2557-2566.
39. Hazel-Fernandez LA, Klorman R, Wallace JM, Cook S. Methylphenidate improves aspects of executive function in African American children with ADHD. J Atten Disord. 2006;9(4):582-589.
40. Kempton S, Vance A, Maruff P, Luk E, Costin J, Pantelis C. Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med. 1999;29(3):527-538.
41. Qian Y, Cao QJ, Wang YF. Effect of extended-release methylphenidate on the ecological executive function for attention deficit hyperactivity disorder [in Chinese]. Beijing Da Xue Xue Bao. 2007;39(3):299-303.
42. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437-1448.
43. Brown TE, Holdnack J, Saylor K, et al. Effect of Atomoxetine on Executive Function Impairments in Adults with ADHD [published online ahead of print December 21, 2009]. J Atten Disord.
44. Gioia GA, Isquith PK, Guy SC, Kenworthy L. BRIEF: Behavior Rating Inventory of Executive Function: Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc; 2000.
45. Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19(6):649-662.
46. Stavro GM, Ettenhofer ML, Nigg JT. Executive functions and adaptive functioning in young adult attention-deficit/hyperactivity disorder. J Int Neuropsychol Soc. 2007;13(2):324-334.
47. Rabbit P. Introduction: Methodologies and models in the study of executive function. In: Rabbit P, ed. Methodology of Frontal and Executive Function. Psychology Press Ltd; 1997.
48. Alderman N, Burgess PW, Knight C, Henman C. Ecological validity of a simplified version of the multiple errands shopping test. J Int Neuropsychol Soc. 2003;9(1):31-44.